SMARCA2 and neuroblastoma: Depmap Predictability function analysis indicates that NB cell lines with lower expression of SMARCA2 tend to be more sensitive to the loss of SMARCA4 (Appendix Fig. S1G), which suggests that targeting both SMARCA2 and SMARCA4 with PROTAC degraders is a promising approach in treating NB patients.